Company intelligence / Profile preview
Riva
South San Francisco, California, United Statesrivatx.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Riva Therapeutics is a precision oncology company dedicated to developing next-generation therapeutics targeting the DNA damage response (DDR) pathway. The company leverages a proprietary platform to identify and validate novel synthetic lethal interactions, aiming to treat cancers with specific genetic vulnerabilities. Founded by industry veterans, Riva focuses on small molecule inhibitors that can overcome resistance to current DDR therapies. Their approach integrates advanced computational biology with deep mechanistic insights to build a robust pipeline of oncology candidates. Headquartered in South San Francisco, the firm is backed by leading venture capital firms such as OrbiMed and F-Prime Capital.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Riva.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Riva.